



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 13:04
Last Report Issued 08/19/2016 14:40

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 3265B
Patient ID 3265B
Chain 15002163
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 15002163
Received 08/19/2015 06:40

Sample ID 15002163-001
Matrix Blood
Patient Name 3265B
Patient ID 3265B
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

3265B Oxcarbazepine / Eslicarbazepine Acetate as Metabolite, Blood

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

10-Hydroxycarbazepine	None Detected	mcg/mL	0.50	
Synonym(s): Licarbazepine; Oxcarbazepine/Eslicarbazepine Acetate Metabolite				

Therapeutic serum range: 10 - 35 mcg/mL.

The ratio of whole blood concentration to serum or plasma concentration is approximately 1.2-1.4.

This test is not chiral specific. The reported concentration represents racemic 10-Hydroxycarbazepine in patients who have taken Oxcarbazepine (Trileptal®) and S-10-Hydroxycarbazepine in patients who have taken Eslicarbazepine Acetate (Aptiom®).

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.